A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

ClinicalTrials.gov ID: NCT05536141

Public ClinicalTrials.gov record NCT05536141. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521 Monotherapy and Combination Therapies in Participants With Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Study identification

NCT ID: NCT05536141
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Arcus Biosciences, Inc.; Industry
Enrollment: 362 participants

Conditions and interventions

Conditions

Interventions

Cabozantinib Drug
Ipilimumab Drug
Zimberelimab Drug
casdatifan Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 25, 2022
Primary completion: Feb 28, 2029
Completion: Feb 28, 2029
Last update posted: Apr 30, 2026

2022 – 2029

United States locations

U.S. sites: 20
U.S. states: 15
U.S. cities: 16

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35294	Recruiting
Research Site	San Diego	California	92093	Recruiting
Research Site	Santa Monica	California	90404	Recruiting
Research Site	Miami	Florida	33136	Recruiting
Research Site	Atlanta	Georgia	30322-1013	Recruiting
Research Site	Louisville	Kentucky	40202	Recruiting
Research Site	New Orleans	Louisiana	70121	Recruiting
Research Site	Baltimore	Maryland	21287	Recruiting
Research Site	Boston	Massachusetts	02215	Recruiting
Research Site	Detroit	Michigan	48201	Recruiting
Research Site	Detroit	Michigan	48202	Recruiting
Research Site	Omaha	Nebraska	68124	Recruiting
Research Site	New York	New York	10029	Recruiting
Research Site	New York	New York	10065	Recruiting
Research Site	Cleveland	Ohio	44106	Recruiting
Research Site	Cleveland	Ohio	44195	Recruiting
Research Site	Pittsburgh	Pennsylvania	15232	Recruiting
Research Site	Nashville	Tennessee	37203	Recruiting
Research Site	Nashville	Tennessee	37240	Recruiting
Research Site	San Antonio	Texas	78229	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05536141, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05536141 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →